SCB-1019T for Respiratory Syncytial Virus
Recruiting at 4 trial locations
XP
Overseen ByXuesong Pei, MD
Age: 18+
Sex: Any
Trial Phase: Phase 1
Sponsor: Clover Biopharmaceuticals USA, LLC
What You Need to Know Before You Apply
What is the purpose of this trial?
CLO-SCB-1019-002 is the first study of SCB-1019T vaccine for revaccination in older adults who were previously vaccinated with AREXVY. The safety, tolerability and immunogenicity of SCB-1019T are assessed.
Do I have to stop taking my current medications for the trial?
The trial does not specify if you need to stop taking your current medications. However, it mentions that participants with stable medical conditions can be included, suggesting that you might not need to stop your medications if your condition is stable.
What safety data exists for SCB-1019T or similar treatments for RSV?
What data supports the effectiveness of the drug SCB-1019T for treating Respiratory Syncytial Virus?
Are You a Good Fit for This Trial?
This trial is for healthy adults aged 60-85 who previously received the AREXVY vaccine. Participants must be able to consent, follow the study plan, and have stable pre-existing medical conditions without significant treatment changes or hospitalization in the past 3 months.Inclusion Criteria
I am healthy or have stable health conditions.
I need to check the full list of requirements in the study protocol.
I am willing and able to follow all study requirements.
See 2 more
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
2-4 weeks
Treatment
Participants receive either SCB-1019T, AREXVY, or placebo on Day 1
1 day
1 visit (in-person)
Follow-up
Participants are monitored for safety and effectiveness after treatment
6 months
What Are the Treatments Tested in This Trial?
Interventions
- SCB-1019T
Trial Overview The SCB-1019T vaccine is being tested for its safety and ability to provoke an immune response (immunogenicity) when given as a revaccination to older adults who had earlier been vaccinated with AREXVY.
How Is the Trial Designed?
4Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: Group 2 (SCB-1019T)Experimental Treatment1 Intervention
50 adults to receive high dose SCB-1019T at Day 1
Group II: Group 1 (SCB-1019T)Experimental Treatment1 Intervention
50 adults to receive low dose SCB-1019T at Day 1
Group III: Group 3 (AREXVY)Active Control1 Intervention
50 adults to receive AREXVY at Day 1
Group IV: Group 4 (Placebo)Placebo Group1 Intervention
10 adults to receive Placebo at Day 1
Find a Clinic Near You
Who Is Running the Clinical Trial?
Clover Biopharmaceuticals USA, LLC
Lead Sponsor
Trials
1
Recruited
160+
Published Research Related to This Trial
In a trial involving 43 infants at risk for RSV, the monoclonal antibody SB 209763 showed a good safety profile with only a few adverse events related to the drug, indicating it is generally safe for use in this population.
While SB 209763 demonstrated some ability to increase neutralization and fusion inhibition titers, it did not significantly reduce the incidence of RSV infections compared to placebo, suggesting that higher doses may be needed for effective protection against RSV lower respiratory tract disease.
NCBI (Pubmed)
pubmed.ncbi.nlm.nih.gov
Safety and pharmacokinetics of an intramuscular monoclonal antibody (SB 209763) against respiratory syncytial virus (RSV) in infants and young children at risk for severe RSV disease.Meissner, HC., Groothuis, JR., Rodriguez, WJ., et al.[2020]
The investigational ChAd155-RSV vaccine was found to have a safety profile similar to other childhood vaccines, with most adverse events occurring at rates comparable to or lower than those of active comparators.
The vaccine induced a strong immune response in infants, with higher RSV neutralizing titers and antibody concentrations compared to the comparator group, and there was no evidence of vaccine-associated enhanced respiratory disease (VAERD).
NCBI (Pubmed)
pubmed.ncbi.nlm.nih.gov
Safety and immunogenicity of a ChAd155-vectored respiratory syncytial virus vaccine in infants 6-7 months of age: a phase 1/2 randomized trial.Sáez-Llorens, X., Norero, X., Mussi-Pinhata, MM., et al.[2023]
Citations
Albuterol responsiveness in infants with respiratory failure caused by respiratory syncytial virus infection. [2019]
Emergency room management of acute bronchiolitis: a randomized trial of nebulized epinephrine. [2013]
Effect of inhaled nitric oxide on respiratory mechanics in ventilated infants with RSV bronchiolitis. [2020]
Use of helium-oxygen mixture (Heliox®) in the treatment of obstructive lower airway disease in a pediatric emergency department. [2020]
Dexamethasone in salbutamol-treated inpatients with acute bronchiolitis: a randomized, controlled trial. [2019]
1,4-Benzodiazepines as inhibitors of respiratory syncytial virus. [2011]
Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody, when administered to RSV-infected children. [2017]
Safety and pharmacokinetics of an intramuscular monoclonal antibody (SB 209763) against respiratory syncytial virus (RSV) in infants and young children at risk for severe RSV disease. [2020]
Safety and immunogenicity of a ChAd155-vectored respiratory syncytial virus vaccine in infants 6-7 months of age: a phase 1/2 randomized trial. [2023]
Live Respiratory Syncytial Virus Attenuated by M2-2 Deletion and Stabilized Temperature Sensitivity Mutation 1030s Is a Promising Vaccine Candidate in Children. [2021]
Other People Viewed
By Subject
By Trial
Related Searches
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.